Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “glp1 Agonist”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07202247
What this trial is testing

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

Who this might be right for
Prostate CarcinomaRecurrent Prostate Carcinoma
City of Hope Medical Center 60
Early research (Phase 1)Ended earlyNCT03645408
What this trial is testing

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

Who this might be right for
Alcohol Use Disorder
Boston Medical Center 8
Post-approval studies (Phase 4)UnknownNCT04122716
What this trial is testing

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet

Who this might be right for
Obesity
Signe Torekov 215
Testing effectiveness (Phase 2)Study completedNCT06987513
What this trial is testing

RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

Who this might be right for
Alcohol Use Disorder (AUD)
Altimmune, Inc. 100
Post-approval studies (Phase 4)UnknownNCT03648554
What this trial is testing

Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)

Who this might be right for
Diabetes Mellitus, Type 2NASH - Nonalcoholic Steatohepatitis
Central Hospital, Nancy, France 93
Not applicableNot Yet RecruitingNCT07444073
What this trial is testing

Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock

Who this might be right for
AgingObesity & Overweight
National University of Singapore 440
Early research (Phase 1)Study completedNCT00931372
What this trial is testing

Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2

Who this might be right for
Diabetes Mellitus, Type 2
Sanofi 22
Large-scale testing (Phase 3)Looking for participantsNCT07083154
What this trial is testing

Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)

Who this might be right for
Dementia, MildMild Cognitive ImpairmentType 2 Diabetes
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 420
Large-scale testing (Phase 3)Not Yet RecruitingNCT07668336
What this trial is testing

Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Who this might be right for
Diabetes Mellitus, Type 2
Eli Lilly and Company 170
Not applicableLooking for participantsNCT07272837
What this trial is testing

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

Who this might be right for
Type 2 DiabetesObesitySemaglutide+2 more
University of Alberta 50
Post-approval studies (Phase 4)Not Yet RecruitingNCT07617155
What this trial is testing

GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis

Who this might be right for
Hypertriglyceridemia Induced Acute PancreatitisRecurrent Acute PancreatitisPancreatitis Relapsing+1 more
Peking Union Medical College Hospital 396
Testing effectiveness (Phase 2)Study completedNCT05920889
What this trial is testing

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies

Who this might be right for
StrokeStroke, AcuteStroke, Ischemic+1 more
Chinese University of Hong Kong 140
Not applicableNot Yet RecruitingNCT07032311
What this trial is testing

Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk

Who this might be right for
Type 2 DiabetesLiver Disease
SIPPA Solutions INC 180
Post-approval studies (Phase 4)Enrolling By InvitationNCT05195944
What this trial is testing

Semaglutide vs Sitagliptin

Who this might be right for
Liver Transplant; ComplicationsDiabetes MellitusNASH - Nonalcoholic Steatohepatitis+1 more
University Health Network, Toronto 58
Post-approval studies (Phase 4)Looking for participantsNCT07588438
What this trial is testing

Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.

Who this might be right for
ObesityDiabetes Mellitus, Type 2
Las Rías Medical Center 160
Large-scale testing (Phase 3)Study completedNCT04039503
What this trial is testing

Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

Who this might be right for
Type 2 Diabetes
Eli Lilly and Company 475
Not applicableStudy completedNCT02745470
What this trial is testing

Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain

Who this might be right for
Diabetes Mellitus
Seoul National University Hospital 30
Not applicableLooking for participantsNCT06487832
What this trial is testing

Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness

Who this might be right for
Normal WeightOverweight and ObesityInsulin Sensitivity+1 more
University Hospital Tuebingen 60
Post-approval studies (Phase 4)Looking for participantsNCT07777575
What this trial is testing

Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide

Who this might be right for
Obesity (BMI>30)
Technical University of Munich 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07676331
What this trial is testing

Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial

Who this might be right for
Hormone-receptor-positive Breast CancerEarly Breast Cancer
Universitaire Ziekenhuizen KU Leuven 168
Next Page